A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
Key facts
- Where
- Plovdiv, Sliven, Smolyan, Sofia, Varna, and Yambol, BulgariaSee the 8 sites
- Phase
- Phase 2
Where in Bulgaria
- PlovdivHospital not named in the registryNo longer taking part
- SlivenHospital not named in the registryNo longer taking part
- SmolyanHospital not named in the registryNo longer taking part
- SofiaHospital not named in the registryNo longer taking part
- VarnaHospital not named in the registryNo longer taking part
- VarnaHospital not named in the registryNo longer taking part
- VarnaHospital not named in the registryNo longer taking part
- YambolHospital not named in the registryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Immunovant Sciences GmbH
- Trial code
- NCT07286006
- Record updated
- 29 September 2026
- Original description
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.Read full original descriptionShow less
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.
Inclusion: Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503; Other, more specific inclusion criteria are defined in the protocol.
Exclusion: Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.